Yenos Analytical Launches Multi-Cancer Early Detection Urine Test
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers.
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers.
The collaboration aims to address payer complexity and rising claim denials affecting independent and hospital-based laboratories.
The joint consensus recommendation from AMP, ASCO, and CAP addresses variability in molecular profiling report formats across laboratories.
The CLIA-certified facility is now authorized to operate in all 50 states, expanding biomarker testing capabilities nationwide.
The action follows a federal court order that vacated the 2024 rule, reinstating FDA’s prior policy of enforcement discretion for laboratory-developed tests.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The proteomics company will use capital to advance partner-driven product development and commercial operations from new California headquarters.
Your lab’s success hinges on a reliable sample management system. But outdated tools may be costing you time, accuracy, and compliance. This guide helps you uncover whether your current system is built for today’s challenges or holding your team back. Take the five-question test, score your solution, and see if it’s time for a smarter approach.